UK Introduces New Regulatory Programme to Improve Women’s Healthcare Evidence

A four-year initiative aims to improve clinical research representation and strengthen evidence about medicines and medical devices used by women.

The United Kingdom has introduced a new regulatory programme designed to address longstanding gaps in women’s healthcare research. Announced on November 16, 2026, by the Medicines and Healthcare products Regulatory Agency (MHRA), the initiative aims to improve how medicines and medical devices are studied, evaluated and monitored for women.

The programme comes amid growing recognition that medical research has not always adequately represented women across different stages of life. Differences involving hormones, reproductive health, pregnancy, age and other biological factors can influence how individuals respond to medicines. However, limitations in clinical research have sometimes made it difficult for doctors and regulators to understand those differences with sufficient confidence.

According to the MHRA, an analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023 found that pregnant women were represented in only 1.1 per cent of trials. Breastfeeding women appeared in just 0.6 per cent.

These figures illustrate an important challenge for healthcare researchers. While medicines may be prescribed to women during pregnancy and breastfeeding, the available clinical evidence does not always provide detailed information about their safety and effectiveness in those circumstances.

The regulator’s new Women’s Health Programme will focus on strengthening the evidence available throughout the development and monitoring of medical products. It also aims to encourage pharmaceutical companies, research institutions and technology developers to consider women’s health requirements earlier in the research process.

Another important aspect is the recognition that women’s healthcare extends beyond reproductive conditions. Menstrual health, pregnancy and menopause remain significant areas, but women also experience a wide range of other medical conditions that require appropriate diagnosis, treatment and long-term care.

Research gaps can affect conditions that appear differently in women or occur disproportionately among them. Without sufficient evidence, medical professionals may face greater uncertainty when selecting treatments or interpreting potential side effects.

The programme seeks to improve collaboration between patients, researchers, healthcare professionals and companies developing medicines and medical technologies. Patient participation is particularly important because research priorities should reflect the experiences and needs of the people who will ultimately use the treatments.

The MHRA also intends to support responsible innovation in women’s healthcare technology. The FemTech sector, which includes products and services designed around women’s health requirements, has expanded into areas such as reproductive monitoring, menstrual health, menopause support and long-term condition management.

The regulator estimates that the UK FemTech sector already generates nearly £300 million in annual turnover. Strengthening the evidence base could help researchers and businesses develop products that respond more effectively to unmet medical needs.

However, the initiative will need to achieve more than an increase in clinical trial participation. Better representation must be accompanied by meaningful research designs, appropriate safety monitoring and transparent publication of findings.

For example, including a small number of women in a clinical study does not necessarily provide enough information to establish whether a medicine behaves differently across age groups or reproductive stages. Researchers must also examine whether study populations reflect the diversity of patients who may eventually receive the treatment.

The programme forms part of a wider effort to improve the UK’s regulatory approach to healthcare inequalities. It is intended to operate alongside the government’s renewed Women’s Health Strategy and related work across the country’s healthcare systems.

The initiative also reflects a growing international discussion about the need to make medical research more representative. As healthcare becomes increasingly personalised, regulators and researchers will need stronger evidence about how different patient groups respond to medicines and devices.

The success of the programme will ultimately depend on its implementation. New research standards, better patient involvement and improved communication of medical evidence could help address long-standing uncertainties.

For patients, the central objective is straightforward: medical treatments should be developed and evaluated with the people who will use them properly represented in the evidence.

Exit mobile version